Banca de QUALIFICAÇÃO: GUILHERME CARLOS BEIRUTH FREIRE

Uma banca de QUALIFICAÇÃO de DOUTORADO foi cadastrada pelo programa.
STUDENT : GUILHERME CARLOS BEIRUTH FREIRE
DATE: 29/09/2023
TIME: 08:00
LOCAL: Departamento de Odontologia
TITLE:

USE OF BLUEM IN THE NON-SURGICAL TREATMENT OF PERI-IMPLANT MUCOSITIS: A RANDOMIZED CONTROLLED CLINICAL TRIAL

KEY WORDS:

Peri-implant mucositis; non-surgical treatment; chemical agent.

PAGES: 40
BIG AREA: Ciências da Saúde
AREA: Odontologia
SUMMARY:

Peri-implant mucositis is an inflammatory condition without loss of bone tissue, which occurs in the soft tissues surrounding the implant. Non-surgical treatment combines basic therapy with or without the use of chemical agents. Therefore, this study aims to evaluate the effectiveness of Bluem as a chemical adjuvant in the treatment of periimplant mucositis in a non surgical treatment protocol, considering periodontal and peri-implant clinical parameters (visible plaque index (VPI), gingival bleeding index (GBI), probing depth (PD), bleeding on probing (BOP), microbiological profile of the biofilm and markers of oxidative stress present in saliva identified by UV/VIs spectroscopy (Ultraviolet/Visible) as dosage of malonaldehyde-MDA ; enzyme superoxide dismutaseSOD and glutathione peroxidase-GSH. Patients in this study will be allocated into two groups that will receive non-surgical treatment: 31 patients will receive basic therapy associated with the chemical agent Bluem (test) and 31 patients will receive basic therapy associated with the use placebo (control). Patients will be followed at baseline, 15 days, 3, 6 and 12 months. Data normality will be determined by the Shapiro-Wilk test. Given the non-normality of the data, the Mann-Whitney, Wilcoxon, Friedman and Fisher's Exact tests, as well as the chi-square to verify the association between the dependent and independent variables will be used. In normal data, the corresponding parametric ones will be applied, both using a significance level of 5%. As a result, it is expected that the application of Bluem will prove its effectiveness in the treatment of peri-implant mucositis as a chemical adjuvant and in improving clinical and microbiological parameters.

COMMITTEE MEMBERS:
Presidente - 1660087 - BRUNO CESAR DE VASCONCELOS GURGEL
Interno - 3291876 - ITALO DE MACEDO BERNARDINO
Interna - 1958729 - RUTHINEIA DIOGENES ALVES UCHOA LINS